Literature DB >> 12515971

Immunocytochemical profile of malignant pleural effusions of small-cell lung cancer.

D Tamiolakis1, N Papadopoulos, A Cheva, M Lambropoulou, A Kotini, D Mikroulis, V Didilis, N Bitzikas, G Bougioukas.   

Abstract

BACKGROUND: Small-cell lung carcinoma (SCLC) is a highly malignant tumour of a somewhat distinctive cell type. The aim of this study was to determine the immunocytochemical profile of tumor cells and lymphoid cell in SCLC pleural fluids.
METHODS: Nine cases of malignant pleural fluids of SCLC were studied using cell block preparation. In pleural effusions cytologically proven to be malignant in 9 patients with SCLC, the immunocytological features of tumor cells, together with the determination of lymphocytic subsets were documented.
RESULTS: In all 9 cases, tumor cells reacted with neuron-specific enolase (NSE) (100%), whereas in 6 of 9 cases (66,66%) tumor cell expressed synaptophysin, thyroid transciption factor-1 (TTF-1) and chromogranin A antigens. Phenotyping of the lymphocytes revealed in the majority of cases an expression of CD3 and CD4 antigens (8 and 7 cases, respectively) in contrast to CD8 and CD20 expression (1 and 1 case, respectively).
CONCLUSIONS: The reactivity pattern of the tumor cells with the markers used in our study is a specific for SCLC. No significant difference in the distribution of lymphocytic subpopulations is observed in correlation with other malignant and no malignant processes involving the pleural cavity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12515971

Source DB:  PubMed          Journal:  Minerva Med        ISSN: 0026-4806            Impact factor:   4.806


  1 in total

1.  The cytomorphologic spectrum of small-cell carcinoma and large-cell neuroendocrine carcinoma in body cavity effusions: A study of 68 cases.

Authors:  Walid E Khalbuss; Huaitao Yang; Qian Lian; Abdelmonem Elhosseiny; Liron Pantanowitz; Sara E Monaco
Journal:  Cytojournal       Date:  2011-10-29       Impact factor: 2.091

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.